Literature DB >> 793371

Metabolic epidemiology of colon cancer: enzymic activity of fecal flora.

A Mastromarino, B S Reddy, E L Wynder.   

Abstract

Because of the potential significance of secondary bile acids and cholesterol metabolites formed by the intestinal microflora in the pathogenesis of colon cancer, fecal microbial 7alpha-dehydroxylase and cholesterol dehydrogenase activities were assayed in colorectal cancer patients, patients with adenomatous polyps, asymptomatic controls, and normal controls. The mean 7alpha-dehydroxylase activity per 100 mg of dry feces per 2 hr incubation for colorectal cancer patients was significantly greater than either asymptomatic controls or normal controls. Patients with polyps had greater activity than controls, but did not differ significantly from the cancer patients or asymptomatic controls. The mean cholesterol dehydrogenase activity for colorectal cancer patients was significantly greater than controls. Patients with polyps also had greater activity than controls. No differences in the level of fecal beta-glucuronidase activity were found among the four risk groups. These data support the concept that patients with colorectal cancer are more able to convert primary bile acids and cholesterol to microbial products in colon contents than are controls. Such differences in the activity of intestinal microflora may serve as biochemical indicators that will reflect the enzymic activity of the fecal flora as well as the key intraluminal compounds in identifying populations at different risk for developing colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 793371     DOI: 10.1093/ajcn/29.12.1455

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  10 in total

Review 1.  [Nutrition and the etiology of colon cancer: from descriptive epidemiology to dietary prevention].

Authors:  R Edenharder
Journal:  Z Ernahrungswiss       Date:  1987-09

2.  Isolation, characterization, and evaluation of wild isolates of Lactobacillus reuteri from pig feces.

Authors:  Deog Yong Lee; Yeon-Soo Seo; Nabin Rayamajhi; Mi Lan Kang; Su In Lee; Han Sang Yoo
Journal:  J Microbiol       Date:  2010-02-04       Impact factor: 3.422

3.  Mutagenic activity in stones from a patient with a congenital choledochal cyst.

Authors:  P Bull; S Guzmán; F Nervi
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

4.  Fecal skatole and indole and breath methane and hydrogen in patients with large bowel polyps or cancer.

Authors:  D A Karlin; A J Mastromarino; R D Jones; J R Stroehlein; O Lorentz
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

5.  Role of bile acids and metabolic activity of colonic bacteria in increased risk of colon cancer after cholecystectomy.

Authors:  E Zuccato; M Venturi; G Di Leo; L Colombo; C Bertolo; S B Doldi; E Mussini
Journal:  Dig Dis Sci       Date:  1993-03       Impact factor: 3.199

6.  Faecal bacterial flora in cancer of the colon.

Authors:  D Vargo; M Moskovitz; M H Floch
Journal:  Gut       Date:  1980-08       Impact factor: 23.059

7.  Production of a fecal mutagen by Bacteroides spp.

Authors:  R L Van Tassel; D K MacDonald; T D Wilkins
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

8.  The intestinal microflora and its colon cancer connection.

Authors:  S L Gorbach
Journal:  Infection       Date:  1982 Nov-Dec       Impact factor: 3.553

9.  Deoxycholic acid formation in gnotobiotic mice associated with human intestinal bacteria.

Authors:  Seiko Narushima; Kikuji Itoha; Yukiko Miyamoto; Sang-Hee Park; Keiko Nagata; Kazuo Kuruma; Kiyohisa Uchida
Journal:  Lipids       Date:  2006-09       Impact factor: 1.646

10.  Pre- and post-weaning diet alters the faecal metagenome in the cat with differences in vitamin and carbohydrate metabolism gene abundances.

Authors:  Wayne Young; Christina D Moon; David G Thomas; Nick J Cave; Emma N Bermingham
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.